Navigation Links
Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium

NUTLEY, N.J., Dec. 9 /PRNewswire/ -- Roche announced today that a total of 20 U.S. and global abstracts involving its oral chemotherapy Xeloda(R) (capecitabine) have been accepted for presentation at the 2008 San Antonio Breast Cancer Symposium (SABCS) in San AntonioDecember 12-14, including a late-breaking study in early breast cancer to be presented on Sunday, December 14, by the Finnish Breast Cancer Group.

Two U.S. abstracts to be presented at the meeting compare the impact of chemotherapy-related costs on direct medical expenditures among patients with metastatic breast cancer who were treated with oral Xeloda monotherapy compared with vinorelbine monotherapy in one study or gemcitabine monotherapy in the other. The data showed that metastatic breast cancer patients treated with Xeloda monotherapy had statistically significant lower total health care costs than patients treated with vinorelbine monotherapy or gemcitabine monotherapy.

The third U.S. abstract demonstrated the accuracy of using p53 gene mutations to predict short-term clinical and pathological responses in women with operable early stage breast cancer in the Phase II XeNA (Xeloda in NeoAdjuvant) trial. The fourth U.S. abstract compares the characteristics of and survival among North Carolina metastatic breast cancer patients treated with Xeloda or taxane monotherapy.

-- Dec. 14, 7:00 to 9:00 a.m., [Poster No. 6107], Capecitabine is associated with lower chemotherapy-related expenditures than those associated with vinorelbine in women with metastatic breast cancer (Lead Author: Michael Lee)

-- Dec. 14, 7:00 to 9:00 a.m., [Poster No. 6108], Capecitabine is associated with lower chemotherapy-related expenditures than those associated with gemcitabine in women with metastatic breast cancer (Lead Author: Michael Lee)

-- Dec. 14, 7:00 to 9:00 a.m., [Poster No. 6047], p53 mutational status, but not immunohistochemical staining (IHC), is associated with a clinical response of the primary tumor in women receiving neoadjuvant docetaxel-capecitabine chemotherapy for locally advanced breast cancer (Lead Author: Jeffrey Ross)

-- Dec. 14, 7:00 to 9:00 a.m., [Poster No. 6091], Survival outcome is similar for first-line chemotherapy with capecitabine or taxane for metastatic breast cancer (Lead Author: Gretchen Kimmick)

The majority of the 15 ex-U.S. abstracts being presented highlight Xeloda as a cornerstone of combination treatment. The remaining Xeloda abstract is a non-Roche sponsored study.

About XELODA (capecitabine)

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug.

Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda. For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.

Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Xeloda is contraindicated in patients with severe renal impairment. For patients with moderate renal impairment, dose reduction is required.

The most common adverse events (greater than or equal to 20%) of Xeloda monotherapy were diarrhea, nausea, stomatitis and hand-foot syndrome. As with any cancer therapy, there is a risk of side effects, and these are usually manageable and reversible with dose modification or interruption.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. For additional information about the U.S. pharmaceuticals business, visit our website Product and treatment information for U.S. healthcare professionals is available at

    All trademarks used or mentioned in this release are protected by law.

     Contacts: Ginny Valenze
               Office: 973-562-2783
               Cell: 973-943-9219

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. State Medicaid Programs to Spend $1.6 Trillion on Long-Term Care over the Next Twenty Years
2. Twenty of Americas Most Promising Scientists Selected as 2008 Pew Scholars in the Biomedical Sciences
3. MAP Pharmaceuticals to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
4. BD to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
5. Medco CEO to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
6. ev3 Inc. to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
7. Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008
8. Twenty-Five Individuals Honored by Yoplait(R) for Making Extraordinary Strides in the Fight Against Breast Cancer
9. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
10. Top Twenty Health Plan Websites Named by
11. Memory Pharmaceuticals Announces Six Abstracts Accepted for Presentation at Society for Neuroscience Meeting
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone ... member, close friend, or animal pass away, death lives among us. It is your ... Coming from a family of 11 children, author T Sky understands that she may ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming ... value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel ...
(Date:11/30/2015)... IL (PRWEB) , ... November 30, 2015 , ... The ... an emerging pharmaceutical company. Because it is so important to this key industry segment, ... Factors in your IND Filing” on December 4th at 11am EST. , Federal law ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. ... Surgical Mesh technology for soft tissue repair in the US via Insightra’s national ... resorbable surgical mesh intended to support and reinforce soft tissue for 6-9 months ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... & Laser Center is one of a select few plastic surgeons in the ... non-surgical fat removal. , SculpSure™ is the world’s first heat-induced laser treatment for ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... -- Booth #4303 – The Imaging Components business of Varian ... array of products in a new booth (#4303) at the ... America in Chicago this ... components "At the Heart of Imaging." Products will include a ... Claymount brand, and computer-aided diagnostic software from MeVis as well ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
Breaking Medicine Technology: